Compare DexCom, Inc. (DXCM) vs Nike Inc (NKE) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Nike (NKE) trades at $42.86, down 2.06% today, with a bearish technical signal and recent earnings beats. Revenue declined to $46.31B in 2025, with net income margin at 6.7%. The stock shows strong profitability with ROE of 22.14% but faces headwinds in China and EMEA. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting 18.5% upside.

Outlook remains cautious near-term due to sales pressure and margin compression, but long-term brand strength and digital DTC strategy offer recovery potential. Key risks include consumer demand softness and competitive pressures. The stock presents a contrarian opportunity if execution improves, supported by institutional confidence.